tumor antigens

tu·mor an·ti·gens

1. antigens that may be frequently associated with tumors or may be specifically found on tumor cells of the same origin (tumor specific);
2. tumor antigens may also be associated with replication and transformation by certain DNA tumor viruses, including adenoviruses and papovaviruses.
Synonym(s): neoantigens (2)

See also: T antigens.

tu·mor an·ti·gens

(tū'mŏr an'ti-jenz)
1. Those antigens that may be frequently associated with tumors or may be specifically found on tumor cells of the same origin (tumor specific).
2. Tumor antigens may also be associated with replication and transformation by certain DNA tumor viruses, including adenoviruses and papovaviruses.
See also: T antigens
Synonym(s): neoantigens, tumour antigens.
References in periodicals archive ?
ADCC is an immune-mediated cell-killing process inherent to macrophages and NK cells that is activated through the engagement of mAbs bound to cell-surface tumor antigens.
Developing additional TCR product candidates retrovirally engineered to target tumor antigens, including for the treatment of colorectal and lung cancers.
Memopi contains ten optimized epitopes, derived from these five tumor antigens, which generate strong specific T cytotoxic responses that lead to the body's immune system preventing the growth of tumor cells expressing these tumor antigens.
Although their presentations vary, syndromes occur when tumor antigens exhibit cross-reactivity to similar antigens expressed by these systems.
These nine articles describe some of the work being done to differentiate markers and use their presence to detect and treat a range of cancers, addressing the characterization of breast cancer subtypes in a large retrospective study, intraocular lymphoma markers, polymorphisms in genes associated with certain T-cell lymphomas, tumor antigens that are markers of minimal residual disease in acute myeloid leukemia, thyroid tumor markers, activity and expression of dipeptidyl peptidase IV and cathepsin H in human cutaneous melanoma compared to other common cancers, melanoma inhibitory activity as a serological marker in metastic melanoma, and the promise (or myth) of the tumor necrosis factor alpha receptors p55 and p75 in ovarian cancer detection.
The discovery of a central role for HMGB1 and TLR2 in overcoming immune ignorance to brain tumor antigens provides a new therapeutic approach in the fight against brain tumors.
Galenica's GPI-0100 series are safe semi-synthetic derivatives from certain natural saponins which have the capability of stimulating Th 1 immunity with production of antigen-specific cytotoxic T cells (CTL) that will seek out and destroy cells carrying abnormal markers such as viral or tumor antigens.
In a twist on that strategy, Raposo and her colleagues loaded laboratory-grown dendritic cells with potential tumor antigens.
The dramatic effect of HAART on KS and PCNSL incidence is postulated to result from partial reconstitution of immunity and enhanced responses to viral and other tumor antigens.
SELECT Therapeutics' ACTIVATE system incorporates tumor antigens into a proprietary molecular form which specifically binds to dendritic cells, allowing uptake and processing to a form which can stimulate the immune system to attack cancer cells.
SAGE is an integral part of Genzyme Molecular Oncology's therapeutic discovery efforts with particular emphasis on the identification of novel tumor antigens and antiangiogenic factors.